TY - JOUR
T1 - Metabolic tumor volume change predicts long-term survival and histological response to preoperative chemotherapy in locally advanced esophageal cancer
AU - Makino, Tomoki
AU - Yamasaki, Makoto
AU - Tanaka, Koji
AU - Masuike, Yasunori
AU - Tatsumi, Mitsuaki
AU - Motoori, Masaaki
AU - Kimura, Yutaka
AU - Hatazawa, Jun
AU - Mori, Masaki
AU - Doki, Yuichiro
N1 - Publisher Copyright:
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Objective: Here, we assess the ability of metabolic tumor volume (MTV) as measured by 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) to evaluate neoadjuvant chemotherapy response for patients with locally advanced esophageal cancer (EC). Background: Optimal methods to evaluate treatment response for EC patients have not yet been established. Although previous studies have reported the value of standardized uptake value (SUV), the accuracy of predicting histological response or long-term survival in EC is limited. Methods: In all, 102 EC patients without distant metastasis who underwent 18F-FDG PET/CT both before and after the preoperative chemotherapy series were analyzed. Results: The median primary tumor MTV values before and after preoperative chemotherapy were 22.55 (range 0.4–183.1) and 2.75 (0–52.9), respectively, and the median MVT reduction rate was 86.5%. We found the most significant difference in survival between PET responders and nonresponders with a cut-off value of 60% MTV reduction, using a 10% stepwise cut-off analysis [2-year progression-free survival (PFS): 79.2 vs 44.4%; hazard ratio (HR) 3.397; P < 0.0001). With this cut-off value, histological response (P ¼ 0.0091), tumor location (P ¼ 0.0102), pT (P ¼ 0.0011), and pN (P ¼ 0.0110) were significantly associated with PET response. Univariate analysis of PFS indicated a correlation between PFS and tumor size, cT, decrease of primary lesion by CT, SUVmax reduction rate, MTV reduction rate, pT, pN, and pM. Multivariate analysis further identified pM (HR 3.063; P ¼ 0.0279) and MTV reduction rate (HR 2.471; P ¼ 0.0263) to be independent prognostic predictors, but not decrease of primary lesion by CT or SUVmax reduction rate. Conclusion: MTV change is clinically useful in predicting both long-term survival and histological response to preoperative chemotherapy in EC patients, after determining the optimal cut-off value based on survival analysis.
AB - Objective: Here, we assess the ability of metabolic tumor volume (MTV) as measured by 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) to evaluate neoadjuvant chemotherapy response for patients with locally advanced esophageal cancer (EC). Background: Optimal methods to evaluate treatment response for EC patients have not yet been established. Although previous studies have reported the value of standardized uptake value (SUV), the accuracy of predicting histological response or long-term survival in EC is limited. Methods: In all, 102 EC patients without distant metastasis who underwent 18F-FDG PET/CT both before and after the preoperative chemotherapy series were analyzed. Results: The median primary tumor MTV values before and after preoperative chemotherapy were 22.55 (range 0.4–183.1) and 2.75 (0–52.9), respectively, and the median MVT reduction rate was 86.5%. We found the most significant difference in survival between PET responders and nonresponders with a cut-off value of 60% MTV reduction, using a 10% stepwise cut-off analysis [2-year progression-free survival (PFS): 79.2 vs 44.4%; hazard ratio (HR) 3.397; P < 0.0001). With this cut-off value, histological response (P ¼ 0.0091), tumor location (P ¼ 0.0102), pT (P ¼ 0.0011), and pN (P ¼ 0.0110) were significantly associated with PET response. Univariate analysis of PFS indicated a correlation between PFS and tumor size, cT, decrease of primary lesion by CT, SUVmax reduction rate, MTV reduction rate, pT, pN, and pM. Multivariate analysis further identified pM (HR 3.063; P ¼ 0.0279) and MTV reduction rate (HR 2.471; P ¼ 0.0263) to be independent prognostic predictors, but not decrease of primary lesion by CT or SUVmax reduction rate. Conclusion: MTV change is clinically useful in predicting both long-term survival and histological response to preoperative chemotherapy in EC patients, after determining the optimal cut-off value based on survival analysis.
UR - http://www.scopus.com/inward/record.url?scp=85059567146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059567146&partnerID=8YFLogxK
U2 - 10.1097/SLA.0000000000002808
DO - 10.1097/SLA.0000000000002808
M3 - Article
C2 - 29727327
AN - SCOPUS:85059567146
SN - 0003-4932
VL - 270
SP - 1090
EP - 1095
JO - Annals of surgery
JF - Annals of surgery
IS - 6
ER -